0001493152-26-022924
SEC filingRegen BioPharma reported net income of $991.9K, a dramatic turnaround from a $19.4K loss last year driven by non-operating gains, despite operating loss widening to -$153.7K from increased expenses across most categories.
Regen BioPharma, Inc. (RGBP) posted Q2 FY2026 revenue of $59.1K, unchanged from the prior year, as licensing arrangements with related parties Zander Therapeutics and Oncology Pharma provided steady income amid the company's focus on biopharma development. This stability underscores reliance on these partnerships while broader commercialization remains in progress.
Operating results reflected heightened costs, with operating income deteriorating to -$153.7K from -$113.3K a year earlier—a 35.6% widening. Management attributes this primarily to increases across all expense categories except rent, signaling expanded activities in research, professional services, and administrative functions typical for a development-stage biotech navigating public markets. The resulting operating margin of -260.2% highlights the period's expense intensity relative to modest revenue, a dynamic common in pre-revenue biopharma firms investing heavily in pipeline advancement.
Net income swung to a $991.9K profit from a -$19.4K loss, propelled by favorable non-operating items that offset operational pressures. This shift demonstrates how derivative-related adjustments can significantly influence bottom-line results in quarters with volatile financial instruments, providing temporary relief but not altering core operational challenges.
Cash flow from operations consumed -$261.2K, up from -$167.6K year-over-year, driven by the same elevated operating expenses noted in the income statement. This acceleration in burn rate aligns with management's commentary on sustained investments in R&D and public company obligations, including professional fees for SEC compliance and reporting.